Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.
Efficacy of a new fluoroquinolone, sitafloxacin (DU-6859a), against Mycobacterium ulcerans was evaluated in vivo using the mouse footpad system. The growth of M. ulcerans in mouse footpads was completely inhibited when mice were fed with sitafloxacin at a dose of 25 mg/kg body weight per day; on the other hand similar effects were observed with ofloxacin at a dose of 100 mg/kg body weight per day. In the presence of rifampin, the above dose of sitafloxacin could be reduced by 75% to achieve total inhibition, while, under similar circumstances, the dose of ofloxacin could be reduced by only 50%. Either used singly or in combination with rifampin, the effects of sitafloxacin were bactericidal. The results suggest that sitafloxacin should be evaluated as a chemotherapeutic agent against M. ulcerans infection.
Dhople
A M
AM
Infectious Diseases Laboratory, Dept of Biological Sciences, Florida Institute of Technology, Melbourne, Florida 32901-6975, USA. adhople@fit.edu
Namba
K
K
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D005528:Foot; D051379:Mice; D008807:Mice, Inbred BALB C; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000662:veterinary; D019911:Mycobacterium ulcerans / Q000187:drug effects* / Q000472:pathogenicity; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology*
D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D024841:Fluoroquinolones; C076246:sitafloxacin; D012293:Rifampin